Feature | December 05, 2014

Study Presented at RSNA Says Even Mild Coronary Artery Disease Puts Diabetic Patients at Risk

Researchers evaluated long-term prognostic value of CCTA in diabetic patients

December 5, 2014 — According to a new long-term study, diabetic patients with even mild coronary artery disease face the same relative risk for a heart attack or other major adverse heart events as diabetics with serious single-vessel obstructive disease. Results of the study were presented at RSNA 2014.

Researchers at the University of British Columbia and St. Paul's Hospital in Vancouver analyzed data from the Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter (CONFIRM) Registry, which was developed to examine the prognostic value of cardiac computed tomography angiography (CCTA) for predicting adverse cardiac events related to coronary artery disease. The registry, which has CCTA data on 40,000 patients from 17 centers around the world, now has five-year follow-up data on 14,000 patients.

The researchers analyzed data on 1,823 diabetic patients who underwent CCTA to detect and determine the extent of coronary artery disease, in which a waxy substance called plaque builds up inside the arteries of the heart. This plaque buildup causes the artery wall to thicken, which limits or, in some cases, completely obstructs blood flow.

Men and women (median age 61.7) in the study were categorized as having no coronary artery disease, mild disease (less than 50 percent of coronary artery narrowed), or obstructive disease (more than 50 percent artery obstruction). Over a 5.2-year follow-up period, there were 246 deaths, representing 13.5 percent of the total study group.

Major adverse cardiovascular event (MACE) data was available on 973 patients. During the follow-up period, 295 (30.3 percent) of the patients experienced a MACE, such as heart attack or a procedure to re-open an obstructed artery called a coronary revascularization.

The researchers found that both obstructive and mild, or non-obstructive, coronary artery disease as determined by CCTA were related to patient deaths and MACE. Most importantly, the study found that the relative risk for death or MACE for a patient with mild coronary artery disease was comparable to that of patients with single vessel obstructive disease.

"Until now, two-year follow-up studies suggested that a diabetic patient with mild or non-obstructive coronary artery disease had a lower risk of major adverse cardiovascular events and death than patients with obstructive disease," said co-author Philipp Blanke, M.D., radiologist at the University of British Columbia and St. Paul's Hospital. "Our five-year follow-up data suggests that non-obstructive and obstructive coronary artery disease as detected by cardiac CTA in diabetic patients are both associated with higher rates of mortality."

Dr. Leipsic said researchers need a better understanding of the evolution of plaque in the arteries and patient response to therapies.

"Cardiac CT angiography is helpful for identifying diabetic patients who are at higher risk for heart events, who may benefit from more aggressive therapy to help modify that risk," says Dr. Leipsic.

Co-authors on the study include Bruce Precious, M.D., Sasi R Ganga Raju, M.B.Ch.B.m Iksung Cho, M.S., Hyuk-Jae Chang, M.D., Fay Lin, M.D., Stephan Achenbach, M.D., Daniel S. Berman, M.D., Matthew J. Budoff, M.D., Tracy Q. Callister, M.D., Mouaz Al-Mallah, M.D., Filippo Cademartiri, M.D., Ph.D., Kavitha M. Chinnaiyan, M.D., Benjamin Chow, M.D., Allison Dunning, M.S., Augustin Delago, M.D., Todd C. Villines, M.D., Martin Hadamitzky, M.D., Jorg Hausleiter, M.D., Leslee Shaw, Ph.D., Philipp A. Kaufmann, M.D., Ricardo C. Cury, M.D., Gudrun Feuchtner, M.D., Yong-Jin Kim, M.D., Erica Maffei, M.D., Gilbert Raff, M.D., Gianluca Pontone, M.D., Daniele Andreini, M.D., Hugo M. Marques, M.D., Ronen Rubinshtein, M.D., Millie Gomez, M.D. and James K. Min, M.D.

 

For more information: www.rsna.org

Related Content

iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
360 Photos | 360 View Photos | June 14, 2018
This is a 360 degree image from the Canon Aquilion 64-slice...
360 Photos | 360 View Photos | May 02, 2018
This is a 360 degree image from the Canon Aquilion One 320-slice computed tomography (CT) system installed at...
iSchemaView Receives FDA Clearance for Rapid CTA
Technology | CT Angiography (CTA) | May 01, 2018
Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug...
HeartFlow FFRct Analysis Added to ITP Payment Program in the U.K.
News | CT Angiography (CTA) | April 25, 2018
HeartFlow Inc. announced that the National Health Service (NHS) England has chosen the HeartFlow FFRct (fractional flow...
New Policy Decisions Give Millions Access to HeartFlow FFRct Analysis
News | Cardiac Imaging | February 01, 2018
February 1, 2018 – HeartFlow announced that seven new commercial payers issued positive medical policies covering the
Overlay Init